Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George I Papakostas, M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R01MH081240 (PAPAKOSTAS, GEORGE I) Apr 15, 2008 - Mar 31, 2014
    NIH
    1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
    Role: Principal Investigator
  2. K23MH069629 (PAPAKOSTAS, GEORGE I) Jan 27, 2004 - Aug 31, 2009
    NIH
    S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hock RS, Feeney A, Iovieno N, Murrough JW, Mathew SJ, Iosifescu DV, Fava M, Jha MK, Papakostas GI. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 Dec 12; 84(1). PMID: 36516320.
    Citations:    Fields:    Translation:Humans
  2. Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022 12 01; 79(12):1162-1172. PMID: 36260324; PMCID: PMC9582972.
    Citations:    Fields:    Translation:Humans
  3. Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, DeBattista C, Ionescu DF, Cusin C, Papakostas GI, Jha MK, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1). PMID: 36383742.
    Citations:    Fields:    Translation:Humans
  4. Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022 12; 27(12):5096-5112. PMID: 36071111; PMCID: PMC9763119.
    Citations:    Fields:    Translation:Humans
  5. Feeney A, Hock RS, Fava M, Hernández Ortiz JM, Iovieno N, Papakostas GI. Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis. J Affect Disord. 2022 05 15; 305:55-64. PMID: 35247482.
    Citations: 1     Fields:    Translation:Humans
  6. Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4). PMID: 34133089.
    Citations: 2     Fields:    Translation:Humans
  7. Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132. PMID: 34090255; PMCID: PMC8338746.
    Citations: 2     Fields:    Translation:Humans
  8. McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl S. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021 05 01; 178(5):383-399. PMID: 33726522; PMCID: PMC9635017.
    Citations: 26     Fields:    Translation:Humans
  9. Hoepner CT, McIntyre RS, Papakostas GI. Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence. Nutrients. 2021 Feb 26; 13(3). PMID: 33652997.
    Citations: 1     Fields:    Translation:Humans
  10. Choi KW, Jang EH, Kim AY, Kim H, Park MJ, Byun S, Fava M, Mischoulon D, Papakostas GI, Yu HY, Jeon HJ. Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. J Psychiatr Res. 2021 01; 133:73-81. PMID: 33310645.
    Citations: 7     Fields:    Translation:Humans
  11. Jha MK, Fava M, Freeman MP, Thase ME, Papakostas GI, Shelton RC, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. J Clin Psychiatry. 2020 12 01; 82(1). PMID: 33264819.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  12. Papakostas GI. Happiness and Treatment Outcome in Resistant Depression. J Clin Psychiatry. 2020 11 10; 81(6). PMID: 33176073.
    Citations: 1     Fields:    Translation:Humans
  13. Papakostas GI, Fava M, Freeman MP, Shelton RC, Thase ME, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. Int Clin Psychopharmacol. 2020 11; 35(6):313-321. PMID: 32804742; PMCID: PMC7531498.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  14. Shelton RC, Fava M, Freeman MP, Thase ME, Papakostas GI, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. J Affect Disord. 2020 12 01; 277:478-485. PMID: 32871535.
    Citations: 2     Fields:    Translation:Humans
  15. Johe KK, Kay G, Kumar S, Burdick KE, McIntyre RS, Papakostas GI, Fava M. NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. Ann Clin Psychiatry. 2020 08; 32(3):182-196. PMID: 32722729.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  16. Dichtel LE, Carpenter LL, Nyer M, Mischoulon D, Kimball A, Deckersbach T, Dougherty DD, Schoenfeld DA, Fisher L, Cusin C, Dording C, Trinh NH, Pedrelli P, Yeung A, Farabaugh A, Papakostas GI, Chang T, Shapero BG, Chen J, Cassano P, Hahn EM, Rao EM, Brady RO, Singh RJ, Tyrka AR, Price LH, Fava M, Miller KK. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 10 01; 177(10):965-973. PMID: 32660299; PMCID: PMC7748292.
    Citations: 5     Fields:    Translation:Humans
  17. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604. PMID: 30617276.
    Citations:    Fields:    
  18. Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4). PMID: 32459407.
    Citations: 16     Fields:    Translation:Humans
  19. Papakostas GI, Jackson WC, Rafeyan R, Trivedi MH. Inadequate Response to Antidepressant Treatment in Major Depressive Disorder. J Clin Psychiatry. 2020 05 19; 81(3). PMID: 32433833.
    Citations: 2     Fields:    Translation:Humans
  20. Papakostas GI, Jackson WC, Rafeyan R, Trivedi MH. Overcoming Challenges to Treat Inadequate Response in Major Depressive Disorder. J Clin Psychiatry. 2020 05 12; 81(3). PMID: 32412698.
    Citations:    Fields:    Translation:Humans
  21. Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. J Clin Psychiatry. 2020 05 12; 81(3). PMID: 32412697.
    Citations: 1     Fields:    Translation:Humans
  22. Trivedi MH, Papakostas GI, Jackson WC, Rafeyan R. Implementing Measurement-Based Care to Determine and Treat Inadequate Response. J Clin Psychiatry. 2020 05 05; 81(3). PMID: 32369683.
    Citations: 1     Fields:    Translation:Humans
  23. Jackson WC, Papakostas GI, Rafeyan R, Trivedi MH. Recognizing Inadequate Response in Patients With Major Depressive Disorder. J Clin Psychiatry. 2020 05 05; 81(3). PMID: 32369684.
    Citations: 1     Fields:    Translation:Humans
  24. Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292. PMID: 32332464; PMCID: PMC7185034.
    Citations: 3     Fields:    Translation:Humans
  25. Freeman MP, Fava M, Dirks B, Jha MK, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depress Anxiety. 2020 05; 37(5):485-495. PMID: 32301591.
    Citations: 1     Fields:    Translation:Humans
  26. Fava M, Dirks B, Freeman MP, Shelton RC, Thase ME, Trivedi MH, Papakostas GI, Liu K, Whitworth T, Stankovic S. 181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. CNS Spectr. 2020 Apr; 25(2):314-315. PMID: 32331041.
    Citations:    
  27. Freeman MP, Fava M, Dirks B, Jha MK, Shelton RC, Thase ME, Trivedi MH, Papakostas GI, Liu K, Whitworth T, Stankovic S. 180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectr. 2020 Apr; 25(2):313-314. PMID: 32331034.
    Citations:    
  28. Papakostas GI. Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need. J Clin Psychiatry. 2020 02 04; 81(2). PMID: 32023369.
    Citations: 3     Fields:    Translation:Humans
  29. Fava M, Mazzone E, Freeman M, Flynn M, Judge H, Hoeppner B, Hock RS, Shui A, Macaluso M, Morrison MF, Carpenter LL, Shelton R, Zajecka J, Papakostas GI. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26. PMID: 33125454.
    Citations:    Fields:    Translation:Humans
  30. Salloum NC, Fava M, Ball S, Papakostas GI. Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review. Mol Psychiatry. 2020 09; 25(9):1967-1974. PMID: 31988433.
    Citations: 2     Fields:    Translation:Humans
  31. Kim K, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Kim H, Na EJ, Yu HY, Jeon HJ. Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. Compr Psychiatry. 2019 11; 95:152140. PMID: 31669792.
    Citations: 3     Fields:    Translation:Humans
  32. Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 09 24; 80(6). PMID: 31556975.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  33. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139. PMID: 31494365.
    Citations: 10     Fields:    Translation:Humans
  34. An JH, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Na EJ, Jang J, Yu HY, Hong JP, Jeon HJ. Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. J Affect Disord. 2019 12 01; 259:349-354. PMID: 31465895.
    Citations: 2     Fields:    Translation:Humans
  35. Salloum NC, Papakostas GI. Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions. J Clin Psychiatry. 2019 06 04; 80(4). PMID: 31163105.
    Citations: 2     Fields:    Translation:Humans
  36. Kim K, Shin JH, Myung W, Fava M, Mischoulon D, Papakostas GI, Choi KW, Na EJ, Seo SW, Seong JK, Jeon HJ. Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder. Sci Rep. 2019 05 16; 9(1):7462. PMID: 31097766.
    Citations: 8     Fields:    Translation:Humans
  37. Papakostas GI, Johe K, Hand H, Drouillard A, Russo P, Kay G, Kashambwa R, Hoeppner B, Flynn M, Yeung A, Martinson MA, Fava M. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2020 07; 25(7):1569-1579. PMID: 30626911.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  38. Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171. PMID: 30641350.
    Citations: 16     Fields:    Translation:Humans
  39. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243. PMID: 30597688.
    Citations: 6     Fields:    Translation:Humans
  40. Choi KW, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Kim DJ, Kim K, Yu HY, Jeon HJ. Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. J Affect Disord. 2019 03 01; 246:157-165. PMID: 30583140.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  41. Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, Nierenberg AA, Fava M. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497. PMID: 30439676.
    Citations: 4     Fields:    Translation:Humans
  42. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603. PMID: 30283029; PMCID: PMC6447473.
    Citations: 70     Fields:    Translation:Humans
  43. Laferton JAC, Vijapura S, Baer L, Clain AJ, Cooper A, Papakostas G, Price LH, Carpenter LL, Tyrka AR, Fava M, Mischoulon D. Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. Front Psychiatry. 2018; 9:424. PMID: 30245644; PMCID: PMC6137256.
    Citations: 6     
  44. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Focus (Am Psychiatr Publ). 2018 Jul; 16(3):328-340. PMID: 32015713; PMCID: PMC6996078.
    Citations: 1     
  45. Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res. 2018 06; 101:72-79. PMID: 29554497.
    Citations: 5     Fields:    Translation:Humans
  46. Iovieno N, Shelton RC, Petrie SR, Cusin C, Fava M, Papakostas GI. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. J Clin Psychiatry. 2018 Jan/Feb; 79(1). PMID: 28749091.
    Citations: 1     Fields:    Translation:Humans
  47. Kim K, Kim SW, Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Seo SW, Cho H, Seong JK, Jeon HJ. Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder. Sci Rep. 2017 Nov 17; 7(1):15772. PMID: 29150619.
    Citations: 27     Fields:    Translation:Humans
  48. Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84. PMID: 29030111.
    Citations: 6     Fields:    Translation:Humans
  49. Mischoulon D, Shelton RC, Baer L, Bobo WV, Curren L, Fava M, Papakostas GI. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017 04; 78(4):449-455. PMID: 27835715.
    Citations: 2     Fields:    Translation:Humans
  50. Ionescu DF, Papakostas GI. Experimental medication treatment approaches for depression. Transl Psychiatry. 2017 03 21; 7(3):e1068. PMID: 28323287.
    Citations: 20     Fields:    Translation:Humans
  51. Heo JY, Kim K, Fava M, Mischoulon D, Papakostas GI, Kim MJ, Kim DJ, Chang KJ, Oh Y, Yu BH, Jeon HJ. Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. J Psychiatr Res. 2017 04; 87:61-70. PMID: 28017916.
    Citations: 22     Fields:    Translation:Humans
  52. Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI. Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016 11; 31(6):341-6. PMID: 27306192.
    Citations: 2     Fields:    Translation:Humans
  53. Papakostas GI. Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change. J Clin Psychiatry. 2016 08; 77(8):e1009. PMID: 27561146.
    Citations:    Fields:    Translation:Humans
  54. Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Heo JY, Kim KW, Kim ST, Kim DJ, Kim DK, Seo SW, Seong JK, Jeon HJ. Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder. Transl Psychiatry. 2016 06 07; 6(6):e835. PMID: 27271861.
    Citations: 32     Fields:    Translation:Humans
  55. Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, Heo JY, Jeon HJ. Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. Psychiatry Investig. 2016 May; 13(3):321-6. PMID: 27247599; PMCID: PMC4878967.
    Citations: 4     
  56. Zajecka JM, Fava M, Shelton RC, Barrentine LW, Young P, Papakostas GI. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60. PMID: 27035404.
    Citations: 7     Fields:    Translation:Humans
  57. Papakostas GI, Martinson MA, Fava M, Iovieno N. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. J Clin Psychiatry. 2016 May; 77(5):e619-24. PMID: 27249092.
    Citations: 1     Fields:    Translation:Humans
  58. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry. 2016 Jun 01; 173(6):575-87. PMID: 27113121.
    Citations: 84     Fields:    Translation:Humans
  59. Ionescu DF, Papakostas GI. Current Trends in Identifying Rapidly Acting Treatments for Depression. Curr Behav Neurosci Rep. 2016 Jun; 3(2):185-191. PMID: 27574579; PMCID: PMC5001565.
    Citations: 4     
  60. Papakostas GI. Identifying patients with depression who require a change in treatment and implementing that change. J Clin Psychiatry. 2016 Feb; 77 Suppl 1:16-21. PMID: 26829433.
    Citations: 3     Fields:    Translation:Humans
  61. Iovieno N, Nierenberg AA, Parkin SR, Hyung Kim DJ, Walker RS, Fava M, Papakostas GI. Relationship between placebo response rate and clinical trial outcome in bipolar depression. J Psychiatr Res. 2016 Mar; 74:38-44. PMID: 26736040.
    Citations: 3     Fields:    Translation:Humans
  62. Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec; 76(12):1635-41. PMID: 26613389.
    Citations: 19     Fields:    Translation:Humans
  63. Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015 Nov; 70:91-7. PMID: 26424427.
    Citations: 24     Fields:    Translation:Humans
  64. Papakostas GI, Shelton RC, Henry ME, Bilello JA. Reply to commentary by Rothschild: "A Blood Test for Depression?". J Clin Psychiatry. 2015 Aug; 76(8):e1038. PMID: 26335092.
    Citations:    Fields:    Translation:Humans
  65. Papakostas GI. Antidepressants and their effect on cognition in major depressive disorder. J Clin Psychiatry. 2015 Aug; 76(8):e1046. PMID: 26335095.
    Citations: 9     Fields:    Translation:Humans
  66. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry. 2015 Oct; 20(10):1142-50. PMID: 26148812.
    Citations: 34     Fields:    Translation:Humans
  67. Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. J Affect Disord. 2015 Oct 01; 185:24-30. PMID: 26142691.
    Citations: 3     Fields:    Translation:Humans
  68. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2015 Dec; 172(12):1251-8. PMID: 26085041; PMCID: PMC4843798.
    Citations: 17     Fields:    Translation:Humans
  69. Papakostas GI. Components of cognitive functioning and their measurement. J Clin Psychiatry. 2015 Jun; 76(6):e16. PMID: 26132678.
    Citations:    
  70. Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D. Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial. Pharmacopsychiatry. 2015 Jul; 48(4-5):141-4. PMID: 26011569.
    Citations: 14     Fields:    Translation:Humans
  71. Papakostas GI, Culpepper L. Understanding and managing Cognition in the Depressed Patient. J Clin Psychiatry. 2015 04; 76(4):418-25. PMID: 25919832.
    Citations: 11     Fields:    Translation:Humans
  72. Papakostas GI, Østergaard SD, Iovieno N. The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry. 2015 Apr; 76(4):456-66. PMID: 25700292.
    Citations: 21     Fields:    Translation:Humans
  73. Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI. Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol. 2015 Mar; 30(2):59-66. PMID: 25438027.
    Citations: 9     Fields:    Translation:Humans
  74. Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI. MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J Clin Psychiatry. 2015 Feb; 76(2):e199-206. PMID: 25742207.
    Citations: 15     Fields:    Translation:Humans
  75. Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015 Mar; 62:56-61. PMID: 25659187.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  76. Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9. PMID: 25544195.
    Citations: 5     Fields:    Translation:HumansAnimals
  77. Papakostas GI, Ionescu DF. Updates and trends in the treatment of major depressive disorder. J Clin Psychiatry. 2014 Dec; 75(12):1419-21. PMID: 25551237.
    Citations: 6     Fields:    Translation:Humans
  78. Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. J Clin Psychiatry. 2014 Dec; 75(12):1411-8. PMID: 25551236.
    Citations: 5     Fields:    Translation:HumansAnimals
  79. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M. Dr. Mischoulon and colleagues reply. J Clin Psychiatry. 2014 Nov; 75(11):e1328-9. PMID: 25470103.
    Citations: 2     Fields:    Translation:Humans
  80. Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, DiPierro M, Cardoos A, Papakostas GI. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Int Clin Psychopharmacol. 2014 Nov; 29(6):332-8. PMID: 24815673.
    Citations: 2     Fields:    Translation:Humans
  81. Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63. PMID: 24813065.
    Citations: 18     Fields:    Translation:Humans
  82. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014 Aug; 164:76-81. PMID: 24856557.
    Citations: 14     Fields:    Translation:Humans
  83. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014 Apr; 75(4):370-6. PMID: 24500245.
    Citations: 28     Fields:    Translation:Humans
  84. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry. 2014 Jan; 75(1):8-14. PMID: 24345473.
    Citations: 41     Fields:    Translation:Humans
  85. Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan; 29(1):16-25. PMID: 24108148.
    Citations: 2     Fields:    Translation:Humans
  86. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014 Feb; 28(2):118-24. PMID: 24352716.
    Citations: 18     Fields:    Translation:Humans
  87. Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2013 Nov; 28(6):312-21. PMID: 23881185.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  88. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O, Mischoulon D. Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety. 2013 Sep; 30(9):873-80. PMID: 23681944.
    Citations: 34     Fields:    Translation:Humans
  89. Trivedi MH, Bandelow B, Demyttenaere K, Papakostas GI, Papakosts GI, Szamosi J, Earley W, Eriksson H. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol. 2013 Sep; 16(8):1733-44. PMID: 23673347.
    Citations: 5     Fields:    Translation:Humans
  90. Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol. 2013 May; 28(3):113-20. PMID: 23485955.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  91. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7. PMID: 23290327.
    Citations: 7     Fields:    Translation:Humans
  92. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74. PMID: 23212058.
    Citations: 69     Fields:    Translation:Humans
  93. Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012 Oct; 73(10):1300-6. PMID: 23140647.
    Citations: 33     Fields:    Translation:Humans
  94. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012 Jul; 57(7):406-13. PMID: 22762295.
    Citations: 24     Fields:    Translation:Humans
  95. Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86. PMID: 22789065.
    Citations: 4     Fields:    Translation:Humans
  96. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012 Jun; 73(6):843-8. PMID: 22687580.
    Citations: 7     Fields:    Translation:Humans
  97. Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother. 2012 May; 46(5):642-9. PMID: 22550279.
    Citations: 4     Fields:    Translation:Humans
  98. Iovieno N, Papakostas GI. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry. 2012 May; 73(5):676-83. PMID: 22569112.
    Citations: 6     Fields:    Translation:Humans
  99. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry. 2013 Mar; 18(3):332-9. PMID: 22158016.
    Citations: 66     Fields:    Translation:Humans
  100. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Dec; 72(12):1660-8. PMID: 22244025.
    Citations: 79     Fields:    Translation:Humans
  101. Papakostas GI, Fan H, Tedeschini E. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol. 2012 May; 22(5):347-55. PMID: 22099607.
    Citations: 16     Fields:    Translation:Humans
  102. Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011 Dec; 72(12):1669-76. PMID: 22053942.
    Citations: 19     Fields:    Translation:HumansAnimals
  103. Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct; 31(5):582-6. PMID: 21869696.
    Citations: 12     Fields:    Translation:Humans
  104. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7. PMID: 21939613.
    Citations: 4     Fields:    Translation:Humans
  105. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012 Feb; 136(3):1174-8. PMID: 21911258.
    Citations: 13     Fields:    Translation:Humans
  106. Papakostas GI. Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol. 2012 Jul; 15(6):841-54. PMID: 21813045.
    Citations: 6     Fields:    Translation:Humans
  107. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012 Oct; 27(7):518-21. PMID: 21665441.
    Citations: 2     Fields:    Translation:Humans
  108. Iovieno N, Tedeschini E, Levkovitz Y, Ameral VE, Papakostas GI. Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials. Int J Neuropsychopharmacol. 2012 Apr; 15(3):289-96. PMID: 21557881.
    Citations: 2     Fields:    Translation:Humans
  109. Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Aug; 72(8):1144-51. PMID: 21536001.
    Citations: 25     Fields:    Translation:Humans
  110. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Apr; 72(4):509-14. PMID: 21527126.
    Citations: 16     Fields:    Translation:Humans
  111. Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI. SAMe and sexual functioning. Eur Psychiatry. 2012 Aug; 27(6):451-4. PMID: 21398094.
    Citations: 7     Fields:    Translation:Humans
  112. Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol. 2011 Mar; 26(2):69-74. PMID: 20962663.
    Citations: 12     Fields:    Translation:Humans
  113. Papakostas GI. Reply to Fleisch et al. Letter. Am J Psychiatry. 2010 Dec; 167(12):1533. PMID: 26650135.
    Citations:    Fields:    
  114. Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J Clin Psychiatry. 2011 Jan; 72(1):98-113. PMID: 21208576.
    Citations: 7     Fields:    Translation:Humans
  115. Papakostas GI. Switching, combination, and augmentation strategies for major depressive disorder. Ann Clin Psychiatry. 2010 Nov; 22(4 Suppl 3):S9-14. PMID: 21180666.
    Citations:    Fields:    Translation:Humans
  116. Papakostas GI, Larsen K. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci. 2011 Apr; 261(3):147-56. PMID: 20859636.
    Citations: 12     Fields:    Translation:Humans
  117. Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21. PMID: 20703198.
    Citations: 1     Fields:    Translation:Humans
  118. Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010 Aug; 22(3):166-71. PMID: 20680189.
    Citations: 4     Fields:    Translation:Humans
  119. Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010 Jul; 25(4):214-7. PMID: 20400905.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  120. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug; 167(8):942-8. PMID: 20595412.
    Citations: 54     Fields:    Translation:Humans
  121. Fornaro M, Iovieno N, Clementi N, Boscaro M, Paggi F, Balercia G, Fava M, Papakostas GI. Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. World J Biol Psychiatry. 2010 Dec; 11(8):991-6. PMID: 20569197.
    Citations: 4     Fields:    Translation:Humans
  122. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8. PMID: 20573327.
    Citations: 21     Fields:    Translation:Humans
  123. Guidi J, Fava GA, Fava M, Papakostas GI. Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med. 2011 Feb; 41(2):321-31. PMID: 20444307.
    Citations: 24     Fields:    Translation:Humans
  124. Tedeschini E, Fava M, Goodness TM, Papakostas GI. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis. Eur Neuropsychopharmacol. 2010 Aug; 20(8):562-7. PMID: 20219330.
    Citations: 5     Fields:    Translation:Humans
  125. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010 Mar; 11(2 Pt 2):300-7. PMID: 20218793.
    Citations: 9     Fields:    Translation:Humans
  126. Yang H, Sinicropi-Yao L, Chuzi S, Youn SJ, Clain A, Baer L, Chen Y, McGrath PJ, Fava M, Papakostas GI. Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Ann Gen Psychiatry. 2010 Feb 26; 9:10. PMID: 20187924.
    Citations: 4     
  127. Papakostas GI, Clain A, Ameral VE, Baer L, Brintz C, Smith WT, Londborg PD, Glaudin V, Painter JR, Fava M. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010 Jan; 25(1):17-21. PMID: 19898245.
    Citations: 5     Fields:    Translation:Humans
  128. Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioglu O, Papakostas GI, Sakamoto K, Terao T, Zhang M. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010; 71 Suppl E1:e08. PMID: 20371035.
    Citations: 21     Fields:    Translation:HumansPHPublic Health
  129. Papakostas GI. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 2010; 71 Suppl E1:e03. PMID: 20371030.
    Citations: 17     Fields:    Translation:Humans
  130. Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, Fava M. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009 Dec; 14(12):688-94. PMID: 20394176.